www.biopharminternational.com March 2018 BioPharm International eBook 33
Outsourcing Resources Market Investment
Contract Services
Investment Update
A review of the latest investments in facilities, equipment, and
acquisitions by biopharma contract service providers.
AMBER LOWRY
B
iopharmaceutical contract service providers
have advanced their capabilities and offer-
ings to help their clients tackle industry
challenges and accelerate innovations. The
following are some of the latest investments
in facilities and equipment by contract service provid-
ers, as well as the mergers and acquisitions market.
MERGERS AND ACQUISITIONS
Charles River Laboratories International announced
on Feb. 13, 2018 that it has entered into a definitive
agreement to acquire MPI Research for approximately
$800 million in cash, expanding its early-stage con-
tract research offerings for the biopharmaceutical and
medical device markets (1).
MPI, a Mattawan, MI-based non-clinical contract
research organization (CRO), provides comprehen-
sive testing services from its one-million-ft2 facility.
The acquisition will add ototoxicity and abuse liabil-
ity capabilities to Charles River's services and will
increase existing capabilities in general and specialty
toxicology, including ophthalmology, juvenile toxic-
ity, molecular biology, and surgery, as well as medical
device testing, as stated by Charles River.
The statement also reports the strategic benefits of
Charles River expanding its biotechnology client base,
Gajus/shutterstock.com